Moxley, Shera A. (Author)
This dissertation probes the rhetoric and reality of rational drug design in the United States biopharmaceutical industry at the close of the Therapeutic Revolution and the dawn of the Biotechnology Era. Starting in the mid-1970s, molecular biologists, genetic engineers, and biotechnology entrepreneurs imagined a new class of biopharmaceuticals for the twenty-first century. Biomedical scientists boasted that they were learning so much about the body's processes at the molecular level that traditional trial-and-error methods of drug discovery soon would be obsolete. They pursued a reductionist molecular etiology of disease and envisioned molecular manipulation of genetic material as the cure. These claims promised nothing less than a radical shift in biopharmaceutical research, from a pharmacology based in chemistry to one based in biology, and from the laborious, random, compound-screening method of drug discovery to rational, efficient drug design. Three case studies demonstrate that even if therapeutic compounds could be produced successfully under conditions of rational design in the industrial laboratory, it did not necessarily follow that they could be evaluated under rational conditions in the hospital clinic, executive boardroom, regulatory arena, or pharmaceutical marketplace. Case studies include Immunetech's anti-allergy pentapeptide, Pentyde; Immunex's recombinant DNA granulocyte-macrophage colony-stimulating factor, Leukine; and Centocor's antisepsis monoclonal antibody, Centoxin. The cases cast biopharmaceutical endeavors as a triangular enterprise space bounded by entrepreneurship, technoscientific change, and regulation. Within this conceptual triangle, the cases explore the factors that stymied linear progress and introduced cul-de-sacs or hairpin turns into drug development pathways. And they delve into the technoscientific, sociopolitical, regulatory, and competitive factors that affected the safety, efficacy, and market viability of rationally designed drugs in the last third of the twentieth century. The contributions of molecular biology to disease understanding, molecular pharmacology to drug discovery, statistical methodologies to clinical drug evaluation, and biotechnologies to drug production processes largely have failed to produce the miracle drugs promised by rational drug design. This dissertation reveals the range of scientific and extra-scientific hurdles to achieving a pharmacopoeia of rationally designed drugs and balances the biotechnology industry's success stories with analyses of some of its failures.
...MoreDescription Cited in ProQuest Diss. & Thes. (2012). ProQuest Doc. ID 1030982756.
Article
Hughes, Sally Smith;
(2001)
Making Dollars out of DNA: The First Major Patent in Biotechnology and the Commercialization of Molecular Biology, 1974--1980
(/isis/citation/CBB000671241/)
Article
Yi, Doogab;
(2009)
The Scientific Commons in the Marketplace: The Industrialization of Biomedical Materials at the New England Enzyme Center, 1963--1980
(/isis/citation/CBB000931983/)
Book
Tone, Andrea;
Watkins, Elizabeth Siegel;
(2007)
Medicating Modern America: Prescription Drugs in History
(/isis/citation/CBB000772110/)
Article
Mohácsi, Gergely;
(2013)
The Adiponectin Assemblage: An Anthropological Perspective on Pharmacogenomics in Japan
(/isis/citation/CBB001213613/)
Book
Carlson, Robert H.;
(2010)
Biology Is Technology: The Promise, Peril, and New Business of Engineering Life
(/isis/citation/CBB001251428/)
Book
Rabinow, Paul;
Dan-Cohen, Talia;
(2005)
A Machine to Make a Future: Biotech Chronicles
(/isis/citation/CBB000651752/)
Article
Smart, Andrew;
Martin, Paul;
(2006)
The Promise of Pharmacogenetics: Assessing the Prospects for Disease and Patient Stratification
(/isis/citation/CBB000770743/)
Article
Yi, Doogab;
(2008)
Cancer, Viruses, and Mass Migration: Paul Berg's Venture into Eukaryotic Biology and the Advent of Recombinant DNA Research and Technology, 1967--1980
(/isis/citation/CBB000850680/)
Article
Miguel García-Sancho;
Dmitriy Myelnikov;
(2019)
Between mice and sheep: Biotechnology, agricultural science and animal models in late-twentieth century Edinburgh
(/isis/citation/CBB803418234/)
Book
Ben Martynoga;
(2018)
Molecular Tinkering: The Edinburgh Scientists Who Changed the Face of Modern Biology
(/isis/citation/CBB777108676/)
Article
Suárez-Díaz, Edna;
García-Deister, Vivette;
(2015)
That 70s Show: Regulation, Evolution and Development beyond Molecular Genetics
(/isis/citation/CBB001510253/)
Article
Greene, Jeremy A.;
(2011)
What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine
(/isis/citation/CBB001230383/)
Article
Greene, Jeremy A.;
(2005)
Releasing the Flood Waters: Diuril and the Reshaping of Hypertension
(/isis/citation/CBB000800013/)
Book
Hughes, Sally Smith;
(2011)
Genentech: The Beginnings of Biotech
(/isis/citation/CBB001221219/)
Article
Worthen, Dennis B.;
(2006)
Early Pharmacy Education at the University of Illinois
(/isis/citation/CBB001020732/)
Book
Rasmussen, Nicolas;
(2014)
Gene Jockeys: Life Science and the Rise of Biotech Enterprise
(/isis/citation/CBB001552207/)
Article
Quirke, Viviane;
(2006)
Putting Theory into Practice: James Black, Receptor Theory and the Development of the Beta-Blockers at ICI, 1958--1978
(/isis/citation/CBB000773951/)
Thesis
Berman, Elizabeth Popp;
(2007)
Creating the Market University: Science, the State, and the Economy, 1965--1985
(/isis/citation/CBB001560644/)
Thesis
Jones, Mark Peter;
(2005)
Biotech's Perfect Climate: The Hybritech Story
(/isis/citation/CBB001560595/)
Thesis
Gozubuyuk, Remzi;
(2007)
The Position of the Firm in Scientific and Alliance Networks: Social Structural Determinants of Innovation in the United States Biotechnology Industry, 1990--2002
(/isis/citation/CBB001561531/)
Be the first to comment!